Switch to ziprazidone treatment is associated with changes in MMN amplitude: a case report.

摘要

Mismatch Negativity (MMN) is an event-related potential component that is automatically evoked when a sequence of unattended repetitive standard auditory stimuli is interrupted by a deviant stimulus (Naatanen et al., 1978). MMN has been proposed for assessing the cognitive deficits that are often observed in patients with schizophrenia and the efficacy of medications aimed at improving these deficits (Braff and Light, 2004). It is an electrophysiological correlate of pre-attentive responses and it is correlated with negative symptoms (Salisbury et al., 2002), cognitive deficits (Baldeweg et al., 2004) and also appears not to be ameliorated by first-generation antipsychotic medications (Pekkonen et al., 2002; Umbricht et al., 1999; Umbritcht et al., 1998). In contrast to static measures of MMN (Liu et al., 2007) showing that MMN was shorter in latency but normal in amplitude in the paranoid personality disorder, new stimulation protocols like the MMN Memory Trace Effect (Baldeweg et al., 2004), have shown a robust correlation of MMN amplitude with cognitive impairment in patients with schizophrenia. On the other hand, new antipsychotic medication has been effective in the treatment of negative symptoms and cognitive deficits. Specifically, Ziprasidone has been described as a drug with special effectiveness on cognition (Harvey et al., 2004) that can be unrelated to an influence of clinical symptom improvement (Malhotra et al., 2006).